Publish time: 2021-12-28 00:00:00
10A-1091027
ENO1 expression is significantly correlated with reduced survival and poor prognosis in many cancer types, including lung cancer. However, there is currently no ENO1-based therapeutic drug approved for clinical use. We generated a chimeric anti-ENO1 monoclonal antibody (chENO1-22) that can decrease cancer cell proliferation and invasion. chENO1-22 inhibits cancer cell invasion by inhibiting ENO1-mediated GSK3β inactivation to promote SLUG protein ubiquitination and degradation. Moreover, chENO1-22 inhibits lung tumor metastasis and prolongs survival time in animal models. Since chENO1-22 reduced tumor progression and metastasis, this therapeutic antibody has a strong clinical potential for treatment of cancer.
1. The therapeutic effect of chENO1-22 against the growth of lung cancer cells.
2. The therapeutic effect of chENO1-22 against lung cancer cell metastasis.
3. The detailed mechanism in suppressing lung cancer metastasis of chENO1-22 antibody has been resolved.
chENO1-22 can reduce tumor progression and metastasis of lung cancer, and has great potential for clinical therapeutic applications.
Han-Chung Wu and Hsin-Jung Li
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Development of a therapeutic monoclonal antibody against ENO1